REPLACE研究:中危PAH患者从PDE5i转换为利奥西呱的随机对照试验
REPLACE是一项多中心开放标签随机对照试验,纳入226例中危PAH患者,比较从PDE5i转换为利奥西呱与继续PDE5i治疗的效果。
要点
- 中危PAH患者从PDE5i转换为利奥西呱可显著提高24周临床改善率。
- 转换治疗组临床恶化事件(1% vs 9%)显著低于继续PDE5i组。
- 利奥西呱组低血压(14%)、头痛(13%)和消化不良(9%)较常见。
核心结论
- 在中危PAH患者中,从PDE5i转换为利奥西呱较继续PDE5i治疗显著改善24周临床改善率并减少临床恶化事件。
研究设计与样本
- 多中心、开放标签、随机对照试验,在22个国家81个肺高血压中心开展。
- 纳入18-75岁中危PAH患者,随机1:1分为利奥西呱组(n=111)和PDE5i组(n=115),按PAH病因分层。
- 主要终点为24周临床改善,定义为无临床恶化且6MWD、WHO功能分级和NT-proBNP三项中至少两项达到预设改善。
主要发现
- 最常见不良事件:利奥西呱组为低血压15例(14%)、头痛14例(13%)、消化不良10例(9%);PDE5i组为头痛8例(7%)、咳嗽7例(6%)、上呼吸道感染7例(6%)。
- 严重不良事件:利奥西呱组8/111(7%)vs PDE5i组19/114(17%);PDE5i组死亡4例。
关键数值与推荐
- 入组标准:有症状PAH,中危(依据ESC/ERS指南WHO功能分级和6MWD阈值),随机前接受PDE5i(±内皮素受体拮抗剂)至少6周。
临床怎么用
- 对于中危PAH患者,若PDE5i治疗反应不足,可考虑转换为利奥西呱作为治疗升级策略。
- 转换时需监测低血压、头痛和消化不良等不良事件。
局限性
- 开放标签设计可能影响主观终点评估。
- 研究排除了既往使用利奥西呱、30天内使用前列环素类似物或受体激动剂、临床显著限制性或阻塞性肺实质疾病及左心疾病患者。
- 主要终点采用末次观测结转法分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality. METHODS: Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) was an open-label, randomised controlled trial in 81 hospital-based pulmonary hypertension centres in 22 countries. The study enrolled patients aged 18-75 years with symptomatic PAH at intermediate risk of 1-year mortality (based on the European Society for Cardiology-European Respiratory Society guideline thresholds for WHO functional class and 6-min walk distance [6MWD]) who were receiving treatment with a PDE5i with or without an endothelin receptor antagonist for at least 6 weeks before randomisation. Patients were excluded if they had been previously treated with riociguat, had used prostacyclin analogues or prostacyclin receptor agonists within 30 days before randomisation, had clinically significant restrictive or obstructive parenchymal lung disease, or had left heart disease. Patients were randomly assigned (1:1) to remain on PDE5i treatment (oral sildenafil [≥60 mg per day] or oral tadalafil [20-40 mg per day]; the PDE5i group) or to switch to oral riociguat (up to 2·5 mg three times per day; the riociguat group), using an interactive voice and web response system, stratified by cause of PAH. The primary endpoint was clinical improvement by week 24, defined as an absence of clinical worsening and prespecified improvements in at least two of three variables (6MWD, WHO functional class, and N-terminal prohormone of brain natriuretic peptide), analysed using last observation carried forward in all randomly assigned patients with observed values at baseline and week 24 who received at least one dose of study medication (the full analysis set). Secondary endpoints included clinical worsening events. The trial has been completed and is registered with ClinicalTrials.gov, NCT02891850. FINDINGS: Between Jan 11, 2017, and July 31, 2019, 293 patients were screened, of which 226 patients were randomly assigned to the riociguat group (n=111) or to the PDE5i group (n=115). 211 patients completed the study and 14 patients discontinued (seven in each group). One patient assigned to the PDE5i group did not receive treatment, so 225 patients were included in the safety analysis, and one further patient in the PDE5i group had missing components of the composite primary endpoint at baseline, so 224 patients were included in the full analysis set. The primary endpoint was met by 45 (41%) of 111 patients in the riociguat group and 23 (20%) of 113 patients in the PDE5i group; odds ratio [OR] 2·78 (95% CI 1·53-5·06; p=0·0007). Clinical worsening events occurred in one (1%) of 111 patients in the riociguat group (hospitalisation due to worsening PAH) and 10 (9%) of 114 patients in the PDE5i group (hospitalisation due to worsening PAH [n=9]; disease progression [n=1]; OR 0·10 [0·01-0·73]; p=0·0047). The most frequently occurring adverse events were hypotension (15 [14%]), headache (14 [13%]), and dyspepsia (10 [9%]) in the riociguat group, and headache (eight [7%]), cough (seven [6%]), and upper respiratory tract infection (seven [6%]) in the PDE5i group. Serious adverse events were reported in eight (7%) of 111 patients in the riociguat group and 19 (17%) of 114 patients in the PDE5i group. During the study, four patients died in the PDE5i group, one of them during the safety follow-up period. INTERPRETATION: Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality. FUNDING: Bayer AG, Merck Sharp & Dohme.
引用
- Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med. 2021. PMID: 33773120. doi:10.1016/S2213-2600(20)30532-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。